Revelation Biosciences, Inc. (REVB)

Market Cap	5.46M
Revenue (ttm)	n/a
Net Income (ttm)	-13.48M
Shares Out	3.57M
EPS (ttm)	161.00
PE Ratio	0.01
Forward PE	7.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	254,244
Open	1.34
Previous Close	1.37
Day's Range	1.34 - 1.55
52-Week Range	1.27 - 100.80
Beta	0.47
Analysts	Buy
Price Target	15.30 (+900.0%)
Earnings Date	Apr 21, 2023

About REVB

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a pote...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: REVB

Analyst Forecast

According to 7 analysts, the average rating for REVB stock is "Buy." The 12-month stock price forecast is $15.3, which is an increase of 900.00% from the latest price.

Price Target

$15.3

(900.00% upside)

Analyst Consensus: Buy